Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 640 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Acalabrutinib July 30, 2020 Mom Goes From Worried To Mortified After Finding Dark Brown Spot... June 4, 2019 Women Experience More Side Effects from Pelvic Radiation than Realized April 8, 2020 Woman, 88, Had Been Waving from Her Window for Over a... May 13, 2019 Load more HOT NEWS Can a Biopsy Make My Cancer Spread? ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... Oncolytic Virus Enables the Immune System to Attack Tumors
